SUBPART A—Drugs Regarded as Misbranded (§250.11 to §250.12)
- 250.11—Thyroid-containing drug preparations intended for treatment of obesity in humans.
- 250.12—Stramonium preparations labeled with directions for use in self-medication regarded as misbranded.